ASCO 2023 | Who will benefit the most from adjuvant IO in melanoma?
Jason Luke
• 2 Jun 2023
Jason Luke, MD, FACP, University of Pittsburgh, Pittsburgh, PA, discusses unanswered questions regarding the use of adjuvant immunotherapy (IO) in patients with melanoma. A large proportion of patients will receive adjuvant immunotherapy, which leads to overtreatment. Additional biomarkers are needed to effectively find patients who will benefit the most from treatment. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So probably the big issue surrounding adjuvant therapy in general, but certainly in melanoma is the risk of population overtreatment...
So probably the big issue surrounding adjuvant therapy in general, but certainly in melanoma is the risk of population overtreatment. And what we need to think about moving forward in the field are biomarker strategies to try to figure out who really needs the treatment versus who could we defer and just monitor over time.
Read more...
The content of VJOncology is intended for healthcare professionals